Our Covid-19 research programme is constantly evolving. Below is a snapshot of our research projects.

Introduction by Professor Guy Thwaites

This introduction was written in June 2021 

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and its disease, COVID-19, have caused unprecedented disruption globally since they were first described in China in December 2019.

The OUCRU programme has felt the full force of that disruption, with severe lockdowns and waves of infection experienced repeatedly over the last 24 months in Viet Nam, Indonesia and Nepal. However, alongside the disruption has come opportunity, particularly the opportunity to conduct research that helps us understand the medical and social impact of the pandemic and improve the ways we control and treat the virus.

The virus has brought the entire OUCRU Programme together. We have supported one another through many difficult periods when the virus seemed to threaten every aspect of our life and work, and we have found new ways to communicate and collaborate. The consequent research has been remarkable, not least because its conception and conduct has been in some of the most difficult circumstances any of us have ever experienced. We have addressed almost every important aspect of the pandemic, from its societal impact to viral genomic surveillance and COVID-19 therapy. Our work has fostered new collaborations with respective governments and their institutions that have ensured our research is relevant and impactful. These collaborations will have a lasting effect on OUCRU’s standing and future work within the region.

As we update OUCRU’s COVID-19 response in early 2022, much has changed in the last 6 months. The large and devastating waves of the Delta variant have passed, but the Omicron variant is now on the ascendency in Asia. The problems this new variant will cause will be dependent upon the levels of population immunity that it confronts. There are grounds for cautious optimism: Indonesia is well-vaccinated, and Viet Nam has gone from low to very high vaccine coverage in 6 months of extraordinary effort (with >1 million vaccines given a day at times). Nepal seems to have gone through a recent omicron wave with low numbers in hospitals and relatively few deaths.


Jeffrey V Lazarus, Diana Romero, Christopher J Kopka, Salim Abdool Karim, Laith J Abu-Raddad, Gisele Almeida, Ricardo Baptista-Leite, Joshua A Barocas, Mauricio L Barreto, Yaneer Bar-Yam, Quique Bassat, Carolina Batista, Morgan Bazilian, Shu-Ti Chiou, Carlos Del Rio, Gregory J Dore, George F Gao, Lawrence O Gostin, Margaret Hellard, Jose L Jimenez, Gagandeep Kang, Nancy Lee, Mojca Matičič, Martin McKee, Sabin Nsanzimana, Miquel Oliu-Barton, Bary Pradelski, Oksana Pyzik, Kenneth Rabin, Sunil Raina, Sabina Faiz Rashid, Magdalena Rathe, Rocio Saenz, Sudhvir Singh, Malene Trock-Hempler, Sonia Villapol, Peiling Yap, Agnes Binagwaho, Adeeba Kamarulzaman, Ayman El-Mohandes, COVID-19 Consensus Statement Panel
November 1, 2022
DOI: 10.1038/s41586-022-05398-2
ISARIC Clinical Characterization Group; Esteban Garcia-Gallo, Laura Merson, Kalynn Kennon, Sadie Kelly, Barbara Wanjiru Citarella, Daniel Vidali Fryer, Sally Shrapnel, James Lee, Sara Duque, Yuli V Fuentes, Valeria Balan, Sue Smith, Jia Wei, Bronner P Gon%E7alves, Clark D Russell, Louise Sigfrid, Andrew Dagens, Piero L Olliaro, Joaquin Baruch, Christiana Kartsonaki, Jake Dunning, Amanda Rojek, Aasiyah Rashan, Abi Beane, Srinivas Murthy, Luis Felipe Reyes
Sci Data
July 30, 2022
DOI: 10.1038/s41597-022-01534-9
Sunate Chuenkitmongkol, Rontgene Solante, Erlina Burhan, Suwat Chariyalertsak, Nan-Chang Chiu, Dung Do-Van, Masliyana Husin, Kao-Pin Hwang, Sasisopin Kiertiburanakul, Prasad S Kulkarni, Ping-Ing Lee, Rommel Crisenio Lobo, Cao Huu Nghia, Anna Ong-Lim, Sheamini Sivasampu, Jing Lian Suah, Peter Seah Keng Tok, Guy Thwaites SEA Vaccine Effectiveness Expert Working Group
Expert Rev Vaccines
June 24, 2022
DOI: 10.1080/14760584.2022.2092472
1 2 13
Learn More


1 2 4
Skip to content